These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 20698812)
1. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Yan L; Colandrea VJ; Hale JJ Expert Opin Ther Pat; 2010 Sep; 20(9):1219-45. PubMed ID: 20698812 [TBL] [Abstract][Full Text] [Related]
2. In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues. Katschinski DM Acta Physiol (Oxf); 2009 Apr; 195(4):407-14. PubMed ID: 19183336 [TBL] [Abstract][Full Text] [Related]
4. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Higashijima Y; Tanaka T; Nangaku M Expert Opin Drug Discov; 2013 Aug; 8(8):965-76. PubMed ID: 23642028 [TBL] [Abstract][Full Text] [Related]
5. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Nangaku M; Izuhara Y; Takizawa S; Yamashita T; Fujii-Kuriyama Y; Ohneda O; Yamamoto M; van Ypersele de Strihou C; Hirayama N; Miyata T Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2548-54. PubMed ID: 17932321 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in erythropoietic agents in renal anemia. Macdougall IC Semin Nephrol; 2006 Jul; 26(4):313-8. PubMed ID: 16949470 [TBL] [Abstract][Full Text] [Related]
7. Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain. Schneider C; Krischke G; Keller S; Walkinshaw G; Arend M; Rascher W; Gassmann M; Trollmann R Brain Res; 2009 Jul; 1280():43-51. PubMed ID: 19450570 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYND-type zinc finger. Choi KO; Lee T; Lee N; Kim JH; Yang EG; Yoon JM; Kim JH; Lee TG; Park H Mol Pharmacol; 2005 Dec; 68(6):1803-9. PubMed ID: 16155211 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Asikainen TM; Ahmad A; Schneider BK; Ho WB; Arend M; Brenner M; Günzler V; White CW Free Radic Biol Med; 2005 Apr; 38(8):1002-13. PubMed ID: 15780758 [TBL] [Abstract][Full Text] [Related]
13. Giving anemia a boost with inhibitors of prolyl hydroxylase. Denny WA J Med Chem; 2012 Apr; 55(7):2943-4. PubMed ID: 22409479 [TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors. Frohn M; Viswanadhan V; Pickrell AJ; Golden JE; Muller KM; Bürli RW; Biddlecome G; Yoder SC; Rogers N; Dao JH; Hungate R; Allen JR Bioorg Med Chem Lett; 2008 Sep; 18(18):5023-6. PubMed ID: 18755588 [TBL] [Abstract][Full Text] [Related]
15. Gallate, the component of HIF-inducing catechins, inhibits HIF prolyl hydroxylase. Tsukiyama F; Nakai Y; Yoshida M; Tokuhara T; Hirota K; Sakai A; Hayashi H; Katsumata T Biochem Biophys Res Commun; 2006 Dec; 351(1):234-9. PubMed ID: 17056012 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologically induced angiogenesis in transgenic zebrafish. Raghunath M; Sy Wong Y; Farooq M; Ge R Biochem Biophys Res Commun; 2009 Jan; 378(4):766-71. PubMed ID: 19068208 [TBL] [Abstract][Full Text] [Related]
17. HIF-1alpha promotes survival of prostate cells at a high zinc environment. Park SE; Park JW; Cho YS; Ryu JH; Paick JS; Chun YS Prostate; 2007 Oct; 67(14):1514-23. PubMed ID: 17683079 [TBL] [Abstract][Full Text] [Related]
18. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Maxwell PH; Eckardt KU Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456 [TBL] [Abstract][Full Text] [Related]
19. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Jeon H; Kim H; Choi D; Kim D; Park SY; Kim YJ; Kim YM; Jung Y Mol Pharmacol; 2007 Jun; 71(6):1676-84. PubMed ID: 17377063 [TBL] [Abstract][Full Text] [Related]
20. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Sugahara M; Tanaka T; Nangaku M Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]